You are here: Home: Audio Program Guide: BCUC 1 | 2007 Audio: BCUC 1 | 2007
 

Go to interview with Richard M Steingart, MD
Go to Tumor Panel Case Discussions
Go to interview with Dennis J Slamon, MD, PhD
Go to interview with Harold J Burstein, MD, PhD

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Steingart, MD Interview with Richard M Steingart, MD
Chief, Cardiology Service, Memorial Sloan-Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
President, Society of Geriatric Cardiology
New York, New York

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Anthracycline-associated cardiotoxicity
Track 3 Molecular pathogenesis of anthracycline-related cardiotoxicity
Track 4 Congestive heart failure in older women treated with anthracyclines: Analysis of the SEER-Medicare database
Track 5 Factors contributory to congestive heart failure
Track 6 Prognosis of congestive heart failure with normal and depressed ejection fractions

Track 7 Prediction of risk for anthracycline-associated cardiotoxicity
Track 8 Intraindividual and measurement variability of left ventricular ejection fraction (LVEF)
Track 9 Advantages and disadvantages of MUGA versus echocardiography
Track 10 Potential mechanisms of trastuzumab-associated cardiotoxicity
Track 11 Reintroduction of trastuzumab after discontinuation for declines in LVEF
Track 12 Use of cardiotoxic agents in patients with a history of cardiac events
Track 13 Dose-dense AC followed by paclitaxel and trastuzumab and cardiac safety
Track 14 Importance of oncology-cardiology collaboration in patient care
     
  Tumor Panel Case Discussions

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Case discussion: A 60-year-old woman with a node-positive, HER2-positive tumor who had multiple changes to LVEF during ACarrowTH
Track 3 Intraindividual variability in LVEF
Track 4 Selection of an adjuvant chemotherapy regimen to combine with trastuzumab
Track 5 Cardiac safety of dose-dense ACarrowpaclitaxel/ trastuzumab
Track 6 Intraindividual and intraobserver variability of MUGA and echocardiography

Track 7 Duration of concurrent chemotherapy/trastuzumab with dose-dense regimens
Track 8 Utility of protocol-defined guidelines for discontinuing trastuzumab due to decreases in LVEF
Track 9 Optimal duration of adjuvant trastuzumab
Track 10 Clinical decision-making based on surveillance of LVEF
Track 11 Case discussion: A 59-year-old woman with HER2-positive, node-negative breast cancer, no cardiac risk factors and a baseline LVEF of 48 percent
Track 12 Case discussion: A 54-year-old woman with strongly ER-positive, PR-positive, HER2-negative breast cancer and cardiomyopathy
Track 13 Prognosis of idiopathic dilated cardiomyopathy
Track 14 Selection of adjuvant systemic therapy for a patient with significant cardiac disease
Track 15 SEER analysis of long-term cardiotoxicity in women treated with anthracyclines
Track 16 Adjuvant chemotherapy for patients with small, node-negative, HER2-negative tumors
Track 17 Long-term risk of congestive heart failure with adjuvant AC chemotherapy
Track 18 Effect of lifestyle and hormonal changes on cardiac risk
audio
Track 19 Case discussion: A 59-year-old woman with an ER-positive, PR-negative, HER2-positive, node-negative tumor and aortic stenosis secondary to prior mantle radiation therapy for Hodgkin’s disease
Track 20 Selection of adjuvant systemic therapy for a patient with aortic valve disease
audio
Track 21 Case follow-up: Treatment with AC followed by paclitaxel/trastuzumab
audio
Track 22 Cardiac effects of lapatinib and clinical use in patients unable to continue trastuzumab
audio
Track 23 Case discussion: A 52-year-old woman with a 4-cm, ER-negative, PR-negative, HER2-positive, node-positive tumor and pulmonary nodules
audio
Track 24 Acute respiratory syndrome in patients with pulmonary metastases treated with trastuzumab
audio
Track 25 Use of trastuzumab in patients with cardiomyopathy and HER2-positive metastatic disease
audio
Track 26 Treatment after progression on trastuzumab: Continue, switch or combine with lapatinib?
audio
Track 27 Participation in adjuvant clinical trials randomly assigning patients to lapatinib without trastuzumab
audio
Track 28 Selection of hormonal therapy for patients with ER-positive, PR-positive, HER2-positive disease
audio
Track 29 Longer versus shorter duration of adjuvant trastuzumab
audio
Track 30 Hypertension associated with anti-angiogenic agents
audio
Track 31 Unforeseen adverse cardiac effects of biologic agents
audio
     
Slamon, MD Dennis J Slamon, MD, PhD
Professor of Medicine
Chief, Division of Hematology/Oncology
Director of Clinical/Translational Research
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Impact of “holding” trastuzumab due to anthracycline-associated declines in LVEF
Track 3 Long-term effects and reversibility of trastuzumab-associated cardiotoxicity
Track 4 Updated analysis of BCIRG 006 adjuvant trastuzumab trial
Track 5 Safety of incorporating bevacizumab with adjuvant chemotherapy and trastuzumab
Track 6 Retrospective evaluation of cMYC in BCIRG 006
Track 7 Lack of crossover to trastuzumab in patients on the control arm of BCIRG 006

Track 8 Adjuvant trastuzumab in patients with lower-risk HER2-positive disease
Track 9 Response to hormonal therapy in patients with hormone receptor-positive, HER2-positive disease
Track 10 Use of adjuvant trastuzumab in patients with lower-risk disease
Track 11 Cardiotoxicity of docetaxel versus paclitaxel in combination with trastuzumab
Track 12 Adjuvant trastuzumab monotherapy
Track 13 Proposed BCIRG trial to evaluate the addition of bevacizumab to chemotherapy and trastuzumab in the adjuvant setting
Track 14 Continuation of trastuzumab versus switching to lapatinib on disease progression in the metastatic setting
Track 15 BIG 2-06 trial evaluating trastuzumab, lapatinib, the combination or the sequence
Track 16 Dose-dense AC followed by paclitaxel/ trastuzumab
Track 17 Utility of Oncotype DX™ versus central laboratory testing of other prognostic factors
Track 18 Extent of HER2 amplification and response to trastuzumab

     
Burstein, MD Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Background and first interim results of the BCIRG 006 adjuvant trastuzumab clinical trial
Track 3 Updated results of BCIRG 006
Track 4 Update of TOPO II as a predictor of benefit from anthracycline-containing chemotherapy in BCIRG 006
Track 5 Future role of anthracycline-containing chemotherapy regimens
Track 6 Relative cardiac safety of TCH compared to ACarrowTH

Track 7 Phase II study of trastuzumab with bevacizumab as first-line therapy for patients with HER2-positive disease
Track 8 Potentially beneficial and adverse synergy between trastuzumab and bevacizumab
Track 9 NSABP/BCIRG adjuvant trial for HER2-positive disease: TCH with or without bevacizumab